Promise of mGluR2/3 activators in psychiatry
Open Access
- 12 December 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Neuropsychopharmacology
- Vol. 34 (1), 248-249
- https://doi.org/10.1038/npp.2008.156
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007
- Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in MiceThe Journal of pharmacology and experimental therapeutics, 2006
- A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic ActivityThe Journal of pharmacology and experimental therapeutics, 2005
- Metabotropic glutamate receptors as novel targets for anxiety and stress disordersNature Reviews Drug Discovery, 2005
- Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2− trifluoroethylsulfonyl)pyrid-3-ylmethylamineJournal of Medicinal Chemistry, 2003
- Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?2002
- Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?Current Drug Targets-CNS & Neurological Disorders, 2002